Merus Announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer
Merus Announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer
Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics targeting EGFR and LGR5.
Merus N.V.（納斯達克：MRUS）是一家臨床階段的腫瘤學公司，正在開發針對癌症的創新全長多特異性抗體（Biclonics和Triclonics）。今天宣佈，公司在評估重度預處理（3L+）轉移性結直腸癌（mCRC）中使用petosemtamab單藥治療的第二階段試驗中，第一位患者已接受治療。Petosemtamab是一種針對EGFR和LGR5的Biclonics。
The phase 2, open-label trial will evaluate the safety and antitumor activity of petosemtamab monotherapy in 3L+ mCRC, post anti-EGFR therapy. To be eligible for enrollment, patients must lack certain mutations as detected in plasma by ctDNA NGS, including KRAS, NRAS.
該第二階段開放標籤試驗將評估抗EGFR治療後，petosemtamab單藥治療在3L+ mCRC中的安全性和抗腫瘤活性。爲了有資格參加，患者必須在ctDNA NGS檢測的血漿中缺乏某些突變，包括KRAS和NRAS。
譯文內容由第三人軟體翻譯。